There are 2789 resources available
LBA24 - Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of expanded cohort 6 of the COSMIC-021 study
Presenter: Neeraj Agarwal
Session: Proffered Paper session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
577O - PRINCE: Interim analysis of the phase Ib study of <sup>177</sup>Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)
Presenter: Shahneen Sandhu
Session: Proffered Paper session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
LBA25 - Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Andrew Armstrong
Session: Proffered Paper session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
1036O - Relatlimab (RELA) + nivolumab (NIVO) vs. NIVO in previously untreated metastatic or unresectable melanoma: Additional efficacy in RELATIVITY-047
Presenter: F. Stephen Hodi
Session: Proffered Paper session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1207O - Bevacizumab + erlotinib vs erlotinib alone as first-line treatment of pts with EGFR mutated advanced non squamous NSCLC: Final analysis of the multicenter, randomized, phase III BEVERLY trial
Presenter: Maria Carmela Piccirillo
Session: Proffered Paper session - NSCLC, metastatic 1
Resources:
Abstract
Slides
Webcast
LBA44 - Primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L study
Presenter: Hirotsugu Kenmotsu
Session: Proffered Paper session - NSCLC, metastatic 1
Resources:
Abstract
Slides
Webcast
LBA45 - Primary data from DESTINY-Lung01: A phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC)
Presenter: Bob Li
Session: Proffered Paper session - NSCLC, metastatic 1
Resources:
Abstract
Slides
Webcast
LBA46 - Efficacy and safety of poziotinib in treatment-naïve NSCLC harboring HER2 exon 20 mutations: A multinational phase II study (ZENITH20-4)
Presenter: Robin Cornelissen
Session: Proffered Paper session - NSCLC, metastatic 1
Resources:
Abstract
Slides
Webcast
382O - Inhibition of WEE1 is effective in TP53 and RAS mutant metastatic colorectal cancer (mCRC): A randomised phase II trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring
Presenter: Jenny Seligmann
Session: Proffered Paper session - Gastrointestinal tumours, colorectal 1
Resources:
Abstract
Slides
Webcast
386O - Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC)
Presenter: Salvatore Siena
Session: Proffered Paper session - Gastrointestinal tumours, colorectal 1
Resources:
Abstract
Slides
Webcast